AKAP12

Across TCGA pan-cancer cohorts, AKAP12 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated AKAP12 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AKAP12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AKAP12 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

BLCA, LIHC, and SARC are the cancer types where AKAP12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.175	0.603	.003	12	view →
LIHC	DFS	Median	All	0.053	0.553	<.001	6	view →
SARC	DFS	Median	All	0.109	0.632	.038	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LUSC	DFS	Median	II,III,IV	0.213	0.594	.046	3	view →
COAD	DFS	Median	IV	0.028	0.496	<.001	3	view →
BRCA	OS	Median	All	0.851	0.924	.038	2	view →
STAD	DFS	Median	IV	1.000	0.284	.038	2	view →
UCEC	DFS	Median	II,III,IV	0.819	0.432	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

AKAP12–BLCA (OS)

Open the BLCA breakdown →